RedHill Biopharma - Ph III with TALICIA data readout end-2018
In the past few weeks, RedHill has reached several R&D milestones: completion of enrolment for the Phase III TALICIA study for H. pylori...
41 Views
RedHill Biopharma - Continued GI product growth, CD PhIII data in 3M
With its Q118 results, RedHill reported GI product revenues growing by 22% q-o-q to $2.4m in Q118. It also provided updates on its Phase III...
60 Views
RedHill Biopharma - Commercial stage, GI-focused R&D pharma
2017 saw RedHill transformed from a pure drug developer into a commercial-stage, revenue-generating, specialty pharma company focused on...
76 Views
RedHill Biopharma - Successful Phase II with BEKINDA for IBS-D
In October 2017, RedHill announced that one of its core assets, BEKINDA, significantly alleviated symptoms of patients with diarrhoea-predominant...
64 Views
First sales of GI specialty products
RedHill’s strategy to diversify into commercial specialty pharma business has born first fruits with initial sales booked in Q217, in line with...
69 Views
No more insights